Head-to-head comparison of Semaglutide (Ozempic/Wegovy) and Tirzepatide (Mounjaro/Zepbound) for fat loss, diabetes management, and side effects.
Semaglutide and Tirzepatide are the two dominant GLP-1 based weight loss medications. Semaglutide is a GLP-1 receptor agonist; Tirzepatide adds GIP receptor agonism on top of GLP-1, making it a dual agonist. Clinical trials show Tirzepatide produces greater fat loss, but Semaglutide has a longer track record and more established safety data.
Our Verdict
Winner: Tirzepatide (fat loss) / Semaglutide (established safety)
Tirzepatide wins on fat loss — 15–22% body weight reduction vs 10–15% for Semaglutide in clinical trials. Semaglutide wins on established safety data, cardiovascular outcomes evidence, and familiarity. For researchers prioritizing maximum fat loss, Tirzepatide is the stronger compound. For those wanting the most established safety profile, Semaglutide is the better choice.
| Category | Semaglutide | Tirzepatide |
|---|---|---|
| Receptor Targets | GLP-1 (single agonist) | GIP + GLP-1 (dual agonist) |
| Fat Loss (Clinical) | 10–15% body weight at 68 weeks | 15–22% body weight at 72 weeks |
| FDA Approval | Ozempic (T2D), Wegovy (obesity) | Mounjaro (T2D), Zepbound (obesity) |
| Cardiovascular Data | Extensive (SUSTAIN, STEP trials) | Growing (SURPASS-CVOT ongoing) |
| Starting Dose | 0.25mg/week | 2.5mg/week |
| Max Dose | 2.4mg/week (Wegovy) | 15mg/week (Zepbound) |
| Side Effects | Moderate GI effects | Similar GI effects, slightly more nausea |
| Half-life | ~7 days | ~5 days |
Purgo Labs carries pharmaceutical-grade Semaglutide and Tirzepatide with third-party COAs. Use code HEALTH for 15% off.
Tirzepatide produces greater fat loss in clinical trials — 15–22% body weight reduction vs 10–15% for Semaglutide. The added GIP receptor agonism enhances fat cell insulin sensitivity and produces complementary appetite suppression.
Yes, but always restart titration from the lowest dose. GLP-1 tolerance does not carry over to Tirzepatide — starting at an equivalent dose will cause significant GI side effects.
Semaglutide has more established cardiovascular outcomes data from the SUSTAIN and STEP trials, which showed significant reduction in MACE events. Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing.
Use our free peptide calculator to convert your dose into exact syringe units based on your vial concentration.
Purgo Labs provides pharmaceutical-grade research peptides with third-party COAs. Use code HEALTH for 15% off your first order.
Visit Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.